Home/Pipeline/LEU011

LEU011

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Leucid Bio

About Leucid Bio

Leucid Bio is a UK-based biotech translating 20+ years of academic research into a novel CAR-T platform designed for enhanced potency and durability. Founded on the pioneering work of Dr. John Maher at King's College London, the company's 'Lateral CAR' technology reconfigures signaling domains to improve T-cell function and persistence. With its lead asset, LEU011, now in a Phase 1 trial for solid tumors and backed by experienced leadership and notable investors, Leucid aims to address significant unmet needs in oncology, particularly in hard-to-treat cancers where current CAR-T therapies have limited efficacy.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed